早期乳腺癌芳香化酶抑制剂引起骨关节疼痛相关研究进展

Research Progress on Aromatase Inhibitors Causing Arthralgia in Early Breast Cancer

芳香化酶抑制剂(Aromatase Inhibitors, AIs)药物治疗绝经后早期乳腺癌引起的不良反应,影响了患者的日常生活,最常见的就是骨关节疼痛和骨骼肌僵硬,简称为(AI-associated arthralgia, AIA)或AIs诱发的肌肉骨骼综合征(AI-associated musculoskeletal symptoms, AIMSS),AIA涉及多种临床因素和治疗方法,但是目前缺乏对AIA的统一定义及有效的评估工具,AIA没有得到最佳的管理与控制;有研究发现遗传基因变异也可能影响药物的疗效或毒性,目前越来越多的研究致力于寻找遗传生物标志物以改善风险预测、诊断和治疗。本文从AIA临床危险因素、治疗方法和其相关的单核苷酸多态性(Single Nucleotide Polymorphisms, SNP)几个方面出发,叙述了AIA相关研究进展,在帮助医生平衡内分泌治疗、提高患者依从性方面有重大意义。

Adverse reactions caused by drug treatment of early postmenopausal breast cancer, Aromatase In-hibitors (AIs), affect the daily life of patients;the most common is bone joint pain and skeletal mus-cle stiffness, referred to as AI-Associated Arthralgia (AIA), or AI-Associated Musculoskeletal Symp-toms (AIMSS). AIA involves a variety of clinical factors and treatments, but currently there is a lack of a unified definition and effective assessment tools for AIA. AIA was not optimally managed and controlled;Some studies have found that genetic variations may also affect the efficacy or toxicity of drugs, and more and more research is focused on finding genetic biomarkers to improve risk pre-diction, diagnosis and treatment. In this paper, the clinical risk factors, therapeutic methods and Single Nucleotide Polymorphisms (SNP) associated with AIA are reviewed, which is of great signifi-cance in helping doctors balance endocrine therapy and improving patient compliance.